Silexion Therapeutics 주식 (NASDAQ: SLXN)

에 대한 최신 뉴스 Silexion Therapeutics (NASDAQ:SLXN) 주식

Silexion Therapeutics

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

BBWI

SLXN

월요일(25일) 아침 미국 주식 선물이 상승하는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식 몇 가지는 다음과 같다. 배스앤바디웍스, 애질런트, 실렉시온, 우드워드 및 줌 비디오

월요일 주목해야 할 주식: 배스앤바디웍스, 애질런트, 실렉시온, 우드워드 및 줌 비디오

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics Corp

<p>Macquarie  analyst Tim Nollen   maintains Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) with a Neutral and maintains $30 price target.</p>


Price Target

Analyst Ratings

Macquarie Maintains Neutral on Warner Music Gr, Maintains $30 Price Target

Guidance

Baker Hughes Says It Remains Confident In Achieving 20% EBITDA Margin Targets For OFSE This Year And IET In 2026

<p>Macquarie  analyst Tim Nollen   maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Outperform and raises the price target from $500 to $600.</p>


SPOT

Macquarie Maintains Outperform on Spotify Technology, Raises Price Target to $600

Baker Hughes Expects 2025 To Demonstrate Another Strong Year Of EBITDA Growth, Led By IET Segment

<p>Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.63 by 11.11 percent. This is a 37.25 percent increase over earnings of $0.51 per share from the same period last year.  The company reported quarterly sales of $7.36 billion which beat the analyst consensus estimate of $7.08 billion by 4.04 percent.  This is a 7.74 percent increase over sales of $6.83 billion the same period last year.</p>


Earnings Beats

Baker Hughes Q4 2024 Adj EPS $0.70 Beats $0.63 Estimate, Sales $7.36B Beat $7.08B Estimate

<p>Across the recent three months, 4 analysts have shared their insights on AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $10.25, with a high estimate of $11.00 and a low estimate of $9.50. This current average represents a 2.38% decrease from the previous average price target of $10.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738274475_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive AGNC Investment. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Jason Weaver</td>
<td>Jones Trading</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.25</td>
<td>$10.25</td>
</tr>
<tr>
<td>Bose George</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$10.25</td>
<td>$10.75</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.50</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to AGNC Investment. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of AGNC Investment compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of AGNC Investment's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into AGNC Investment's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AGNC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on AGNC Investment analyst ratings.</strong></a></p>
<h2>Discovering AGNC Investment: A Closer Look</h2>
<p>AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.</p>
<h3>AGNC Investment: Delving into Financials</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Challenges:</strong> AGNC Investment's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-59.04%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>55.84%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> AGNC Investment's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.06%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.1%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.01</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AGNC

Assessing AGNC Investment: Insights From 4 Financial Analysts

<p>Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $18.73, a high estimate of $24.00, and a low estimate of $16.00. Witnessing a positive shift, the current average has risen by 19.76% from the previous average price target of $15.64.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738274465_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Upwork by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kunal Madhukar</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Marvin Fong</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$18.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Upwork. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Upwork compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Upwork's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Upwork's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UPWK/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Upwork analyst ratings.</strong></a></p>
<h2>About Upwork</h2>
<p>Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to clients.</p>
<h3>Financial Milestones: Upwork's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Upwork displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>10.27%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Upwork's net margin is impressive, surpassing industry averages. With a net margin of <strong>14.32%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Upwork's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.19%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.68%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Upwork's debt-to-equity ratio is below the industry average at <strong>0.9</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


UPWK

Breaking Down Upwork: 11 Analysts Share Their Views

<p>Ratings for Crane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $175.75, with a high estimate of $200.00 and a low estimate of $157.00. This upward trend is evident, with the current average reflecting a 2.03% increase from the previous average price target of $172.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738274456_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Crane. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Summerville</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$170.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$157.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Hold</td>
<td>$176.00</td>
<td>$176.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Crane. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Crane compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Crane's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Crane's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Crane analyst ratings.</strong></a></p>
<h2>Delving into Crane's Background</h2>
<p>Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.</p>
<h3>Unraveling the Financial Story of Crane</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Crane faced challenges, resulting in a decline of approximately <strong>-8.89%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Crane's net margin excels beyond industry benchmarks, reaching <strong>14.89%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Crane's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>5.04%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Crane's ROA excels beyond industry benchmarks, reaching <strong>3.07%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Crane's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.15</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Crane Stands With Analysts

<p>Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for BlackLine, revealing an average target of $71.3, a high estimate of $86.00, and a low estimate of $60.00. Witnessing a positive shift, the current average has risen by 9.69% from the previous average price target of $65.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738274443_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive BlackLine is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koji Ikeda</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Maintains</td>
<td>Buy</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$86.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Chris Quintero</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$51.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BlackLine. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BlackLine compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of BlackLine's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into BlackLine's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on BlackLine analyst ratings.</strong></a></p>
<h2>About BlackLine</h2>
<p>BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their financial close process including account reconciliations, variance analysis of account balances, journal entry capabilities, and certain types of data matching capabilities. The majority of the revenue of the company is earned in the United States.</p>
<h3>BlackLine's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> BlackLine's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>10.09%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> BlackLine's net margin is impressive, surpassing industry averages. With a net margin of <strong>10.39%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.97%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> BlackLine's ROA excels beyond industry benchmarks, reaching <strong>0.96%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.49</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 10 Analysts Discuss BlackLine Stock

<p>4 analysts have shared their evaluations of UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $141.5, a high estimate of $156.00, and a low estimate of $128.00. This current average reflects an increase of 8.02% from the previous average price target of $131.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738274429_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of UMB Financial among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$128.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Nathan Race</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$139.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Brian Wilczynski</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$156.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UMB Financial. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of UMB Financial compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of UMB Financial's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UMBF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on UMB Financial analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind UMB Financial</h2>
<p>UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking, asset management, and health spending solutions. Its customer base includes commercial, institutional, and personal customers across the United States. The company's banking subsidiaries own and operate banking and wealth-management centers mostly throughout the Midwest and Southwest regions of the U.S. Subsidiaries of the holding company and its lead bank, UMB Bank, include mutual fund and alternative investment services groups, single-purpose companies that deal with brokerage services and insurance, and a registered investment advisory. The bank's revenue is split nearly evenly between interest income and noninterest income.</p>
<h3>UMB Financial's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> UMB Financial's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>8.32%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>30.44%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> UMB Financial's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.43%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.25%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> UMB Financial's debt-to-equity ratio is below the industry average at <strong>0.11</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


UMBF

A Glimpse Into The Expert Outlook On UMB Financial Through 4 Analysts

<p>Barrington Research  analyst James Goss   maintains Sirius XM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) with a Outperform and maintains $30 price target.</p>


SIRI

Barrington Research Maintains Outperform on Sirius XM Holdings, Maintains $30 Price Target

<p>Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 8.34% on an annualized basis producing an average annual return of 20.61%. Currently, Alnylam Pharmaceuticals has a market capitalization of $36.14 billion. </p>
<p><strong>Buying $1000 In ALNY:</strong> If an investor had bought $1000 of ALNY stock 15 years ago, it would be worth <strong>$16,726.61</strong> today based on a price of $280.16 for ALNY at the time of writing.</p>
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738274415_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ALNY

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

<p>8 analysts have shared their evaluations of Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $24.62, along with a high estimate of $39.00 and a low estimate of $16.00. Observing a 15.15% increase, the current average has risen from the previous average price target of $21.38. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738274416_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive Pacira BioSciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$25.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pacira BioSciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Pacira BioSciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Pacira BioSciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Pacira BioSciences analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Pacira BioSciences</h2>
<p>Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.</p>
<h3>Financial Insights: Pacira BioSciences</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Pacira BioSciences's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>2.83%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Pacira BioSciences's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-85.11%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Pacira BioSciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-17.62%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-9.06%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Pacira BioSciences's debt-to-equity ratio is below the industry average. With a ratio of <b>0.86</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PCRX

What 8 Analyst Ratings Have To Say About Pacira BioSciences

<p>Financial Institutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FISI#NASDAQ">FISI</a>) reported quarterly adjusted earnings of $0.55 per share which missed the analyst consensus estimate of $0.56. The company reported quarterly sales of $41.63 million which missed the analyst consensus estimate of $42.36 million by 1.71 percent. This is a 4.38 percent increase over sales of $39.89 million the same period last year. Adjusted earnings exclude loss on investment securities of $100.1M or $75M after-tax due to previously disclosed securities portfolio restructurings.</p>


Earnings Misses

FISI

Financial Institutions Q4 Adj EPS $0.55 miss $0.56 Estimate, Sales $41.63M Miss $42.36M Estimate. Adjusted EPS excludes loss on investment securities of $100.1M or $75M after-tax due to previously disclosed securities portfolio restructurings.

Dividends

Walgreens Boots Alliance Says Its Cash Needs Over Next Several Years, Including With Respect To Litigation And Debt Refinancing, Were Important Considerations To Suspend Dividend

<p>Donaldson's advanced air filter technology is set to be featured in the next-generation Freightliner SuperTruck III, further solidifying its position at the forefront of hydrogen fuel cell innovation.</p>


Donaldson Enters Partnership With Daimler Truck North America On Hydrogen Fuel Cell Project

<p>Tigress Financial  analyst Ivan Feinseth   maintains Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) with a Buy and maintains $55 price target.</p>


Tigress Financial Maintains Buy on Verizon Communications, Maintains $55 Price Target

<p><strong>Atlassian</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) just disclosed its Q2 earnings on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Atlassian beat estimated earnings by 26.0%, reporting an EPS of $0.96 versus an estimate of $0.76.</p>
<p>Revenue was up $226.00 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>In the previous quarter, the company beat on EPS by $0.13, resulting in a 19.0% increase change in the share price the following day.</p>
<p>Here's a look at Atlassian's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.64</td>
<td>0.61</td>
<td>0.62</td>
<td>0.62</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.77</td>
<td>0.66</td>
<td>0.89</td>
<td>0.73</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.15B</td>
<td>1.13B</td>
<td>1.10B</td>
<td>1.02B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.19B</td>
<td>1.13B</td>
<td>1.19B</td>
<td>1.06B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Atlassian <a href="https://www.benzinga.com/quote/TEAM/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TEAM

Atlassian Q2 Earnings Assessment

<p><strong>Bancorp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) announced its Q4 earnings on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Bancorp beat estimated earnings by 2.0%, reporting an EPS of $1.15 versus an estimate of $1.13.</p>
<p>Revenue was up $2.14 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>During the previous quarter, the company missed on EPS by $0.08, leading to a 14.000000000000002% drop share price change the next day.</p>
<p>Here's a look at Bancorp's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.12</td>
<td>1.07</td>
<td>1.05</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.04</td>
<td>1.07</td>
<td>1.06</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>99.31M</td>
<td>96.41M</td>
<td>116.51M</td>
<td>90.65M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>93.73M</td>
<td>93.80M</td>
<td>94.42M</td>
<td>92.16M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Bancorp management provided guidance for FY 2025, expecting earnings between $5.25 and $5.25 per share.</p>
<p>To track all earnings releases for Bancorp <a href="https://www.benzinga.com/quote/TBBK/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TBBK

Bancorp Q4 Earnings Assessment

<p><strong>Standex International</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) released its Q2 earnings on Thursday, January 30, 2025 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Standex International beat estimated earnings by 14.000000000000002%, reporting an EPS of $1.91 versus an estimate of $1.67.</p>
<p>Revenue was up $11.41 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous quarter, the company beat on EPS by $0.01, resulting in a 4.0% increase change in the share price the following day.</p>
<p>Here's a look at Standex International's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.70</td>
<td>1.72</td>
<td>1.67</td>
<td>1.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.71</td>
<td>1.76</td>
<td>1.75</td>
<td>1.78</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>181.39M</td>
<td>181.29M</td>
<td>180.14M</td>
<td>182.52M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>170.46M</td>
<td>180.19M</td>
<td>177.27M</td>
<td>178.40M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Standex International <a href="https://www.benzinga.com/quote/SXI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Standex International Earnings Report: Q2 Overview

Silexion Therapeutics (SLXN) announced new preclinical results demonstrating the synergistic efficacy of its proprietary second-generation siRNA ca...

Silexion Therapeutics announces new preclinical results for SIL-204

Silexion Therapeutics drops 18%, prices $5M share offering

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Catalyst Watch: Netflix earnings, Monster Beverage event, drug data, and quantum volatility

Netflix, Procter & Gamble, Johnson & Johnson Report Results In Holiday-Shortened Week

Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings contribute t...

Silexion Therapeutics reports preclinical data for SIL-204

Silexion Therapeutics announces exercise of warrants for $3.3M gross proceeds

Silexion Therapeutics, Tonix Pharmaceuticals, and Trinity Biotech Plc. are the 3&nbsp;Penny Stocks&nbsp;to watch on January 30, 2025, based on&nbsp...

3 Penny Stocks to Watch Now, 1/30/25

In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with a p...

Silexion Therapeutics (SLXN) Gets a Buy from Maxim Group

ACCD

AGEN

AKRO

ALLK

ALTR

ALXO

ARLUF

AZTR

BDTX

BLMZ

CANF

CELH

COST

DELL

DXST

ERNA

ETNB

FBGL

FTNT

GLXZ

GMVHF

GTBP

IBIO

INKT

INTU

ISRG

ITCI

JSPR

KAPA

KURA

LPTX

MMYT

MNST

MSDL

MSFT

MSTR

MVRK

NFLX

NIPG

NLSP

NXST

ONCO

ORKT

PGHL

PHIO

QBTS

QLGN

RGTI

SIEGY

SLRX

SMPL

SNGX

SSNLF

TECX

TNXP

TOPP

TRIB

TSX:VG

TVGN

TWLO

Contracts

Press Releases

Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Health Care

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Market Alert: PESG Releases New Report Highlighting Silexion Therapeutics as an Emerging Leader in the Multi-Billion Dollar Precision Oncology Industry

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

ABVC BioPharma

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AIM ImmunoTech

BioCardia

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Carmell

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

GlycoMimetics

HCW Biologics

Imunon

Immuron Limited - American Depositary Shares

Immuron

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

MetaVia

Mainz Biomed

Nanoviricides

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

PharmaCyte Biotech

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Spruce Biosciences

Turnstone Biologics

Maxim Group

<p>월요일(25일) 아침 미국 주식 선물이 상승하는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식 몇 가지는 다음과 같다</p>
<p><strong>1. 배스앤바디웍스 </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>)</p>
<p><a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">벤징가 프로 데이터</a>에 따르면 오늘 개장 전 실적을 발표하는 배스앤바디웍스의 매출은 15억 8,000만 달러, 주당순이익은 47센트로 예상된다. 주가는 시간외 거래에서 2.6% 상승한 31.51달러를 기록했다.</p>
<p><strong>2. 애질런트 테크놀로지스</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>)</p>
<p>오늘 장 마감 후 실적을 발표하는 애질런트의 분기 주당순이익은 1.41달러, 매출은 16억 7천만 달러로 예상된다. 주가는 시간외 거래서 0.8% 상승한 134.96달러에서 거래되었다.</p>
<p><strong>3. 실렉시온 테라퓨틱스</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>)</p>
<p>실렉시온은 1:9 주식 병합을 발표했다. 주간는 시간외 거래서 11.2% 하락한 0.2725달러에서 거래되었다.</p>
<p class="p1"><em>자세한 내용은<span class="s1"> <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener"><span class="s2">프리마켓</span> <span class="s2">커버리지</span></a></span>를 확인하세요<span class="s1">.</span></em></p>
<p><strong><span >4. </span>우드워드 </strong><span >(NASDAQ:</span><a class="ticker" style="font-size: revert;" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a><span >)</span></p>
<p><span >오늘 장 마감 후 분기 실적을 발표하는 우드위드의 주당순이익은 1.26달러, 매출은 8억 1,101만 달러로 예상된다. 주가는 시간외 거래에서 0.3% 상승한 176.49달러에서 거래되었다.</span></p>
<p><strong><span >5</span></strong><strong >. 줌 비디오 커뮤니케이션스</strong><span > (NASDAQ:</span><a class="ticker" style="font-size: revert;" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a><span >)</span></p>
<p><span >오늘 장 마감 후 실적을 발표하는 줌 비디오의 분기 주당순이익은 1.31달러, 매출은 11억 6천만 달러로 예상된다. 주식은 시간외 거래에서 1.3% 상승한 86.95달러에서 거래되었다.</span></p>
<p><strong><em><span >이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%85%8C%EC%8A%AC%EB%9D%BC%EC%99%80-%EB%A6%AC%EB%B9%84%EC%95%88-%EC%98%81%EC%97%85%EB%B9%84%EB%B0%80-%EC%B9%A8%ED%95%B4-%EC%86%8C%EC%86%A1%EC%97%90%EC%84%9C-4%EB%85%84-%EB%A7%8C%EC%97%90-%ED%95%A9/" target="_blank" rel="noopener">테슬라와 리비안, 영업비밀 침해 소송에서 4년 만에 합의</a></span></em></strong></p>
<p><em>사진 출처: Shutterstock</em></p>
<p class="p1"><em><b>다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.</b></em></p>
<p class="p2"><em><span class="s1">Benzinga Pro</span>의 독점 뉴스를 통해<span class="s1"> </span>수백만 명의 다른 트레이더보다<span class="s1"> </span>더 빠르게<span class="s1"> </span>유용한 투자 뉴스를 확인할 수 있습니다<span class="s1">. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener"><span class="s2"><b>여기를</b></span><b> </b><span class="s2"><b>클릭</b></span></a></span>하여<span class="s1"> 14</span>일 무료 체험을 시작하세요<span class="s1">.</span></em></p>

Comments

Silexion Therapeutics

뉴스

에 대한 최신 뉴스 Silexion Therapeutics (NASDAQ:SLXN) 주식

월요일, 11월 25, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌